Performance Evaluation of the PowerChek MERS (upE & ORF1a) Real-Time PCR Kit for the Detection of Middle East Respiratory Syndrome Coronavirus RNA
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Molecular detection of Middle East respiratory syndrome coronavirus (MERS-CoV) using real-time reverse transcription (rRT)-PCR assays is the method of choice for diagnosis of MERS. We evaluated the performance of the PowerChek MERS (upE & ORF1a) real-time PCR Kit (PowerChek MERS assay; Kogene Biotech, Korea) a one-step rRT-PCR assay for the qualitative detection of MERS-CoV. Methods: We evaluated PowerChek MERS assay performance in comparison with nested RT-PCR and sequencing of the RNA-dependent RNA polymerase (RdRp) and N genes. To evaluate diagnostic sensitivity and specificity, 100 clinical specimens (50 positive and 50 negative for MERS-CoV) were simultaneously tested by using the PowerChek MERS and sequencing assays. Assay performance, including limit of detection and precision, was evaluated in vitro by using MERS-CoV RNA transcripts. Analytical specificity was evaluated with a diverse collection of 16 respiratory virus–positive clinical specimens and 14 respiratory bacterial isolates. Results: The 95% limits of detection of the PowerChek MERS assay for the upE and the open rading frame (ORF)1a were 16.2 copies/μL and 8.2 copies/μL, respectively. No cross-reactivity was observed. The diagnostic sensitivity and specificity of the PowerChek MERS assay were both 100% (95% confidence interval, 91.1–100%). Conclusions: The PowerChek MERS assay is a straightforward and accurate assay for detecting MERS-CoV RNA. The assay will be a useful tool for the rapid diagnosis of MERS and could prove especially important for MERS outbreak control.
Abstract
Background: Molecular detection of Middle East respiratory syndrome coronavirus (MERS-CoV) using real-time reverse transcription (rRT)-PCR assays is the method of choice for diagnosis of MERS. We evaluated the performance of the PowerChek MERS (upE & ORF1a) real-time PCR Kit (PowerChek MERS assay; Kogene Biotech, Korea) a one-step rRT-PCR assay for the qualitative detection of MERS-CoV. Methods: We evaluated PowerChek MERS assay performance in comparison with nested RT-PCR and sequencing of the RNA-dependent RNA polymerase (RdRp) and N genes. To evaluate diagnostic sensitivity and specificity, 100 clinical specimens (50 positive and 50 negative for MERS-CoV) were simultaneously tested by using the PowerChek MERS and sequencing assays. Assay performance, including limit of detection and precision, was evaluated in vitro by using MERS-CoV RNA transcripts. Analytical specificity was evaluated with a diverse collection of 16 respiratory virus–positive clinical specimens and 14 respiratory bacterial isolates. Results: The 95% limits of detection of the PowerChek MERS assay for the upE and the open rading frame (ORF)1a were 16.2 copies/μL and 8.2 copies/μL, respectively. No cross-reactivity was observed. The diagnostic sensitivity and specificity of the PowerChek MERS assay were both 100% (95% confidence interval, 91.1–100%). Conclusions: The PowerChek MERS assay is a straightforward and accurate assay for detecting MERS-CoV RNA. The assay will be a useful tool for the rapid diagnosis of MERS and could prove especially important for MERS outbreak control.
참고문헌 (17)
- Chan JF, "Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease", Clin Microbiol Rev, 28, pp.465~522 (2015)
- "Laboratory testing for Middle East respiratory syndrome coronavirus (MERT-CoV). Interim guidance"[URL]
- Corman VM, "Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction", Euro Surveill, 17, pp.20285~ (2012)
- Corman VM, "Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections", Euro Surveill, 17, pp.20334~ (2012)
- Corman VM, "Performance and clinical validation of the RealStar MERS-CoV Kit for detection of Middle East respiratory syndrome coronavirus RNA", J Clin Virol, 60, pp.168~171 (2014)
- 김미나, "Analytical and Clinical Validation of Six Commercial Middle East Respiratory Syndrome Coronavirus RNA Detection Kits Based on Real-Time Reverse-Transcription PCR", Annals of Laboratory Medicine, 36(5), pp.450~456 (2016), 대한진단검사의학회
- Lu X, "Real-time reverse transcription-PCR assay panel for Middle East respiratory syndrome coronavirus", J Clin Microbiol, 52, pp.67~75 (2014)
- Chan JF, "Development and evaluation of novel real-time reverse transcription-PCR assays with locked nucleic acid probes targeting leader sequences of human-pathogenic coronaviruses", J Clin Microbiol, 53, pp.2722~2726 (2015)
- "Novel coronavirus 2012 real-time RT-PCR assay"[URL]
- Shirato K, "Detection of Middle East respiratory syndrome coronavirus using reverse transcription loop-mediated isothermal amplification (RT-LAMP)", Virol J, 11, pp.139~ (2014)
- 성문우, "External Quality Assessment of MERS-CoV Molecular Diagnostics During the 2015 Korean Outbreak", Annals of Laboratory Medicine, 36(3), pp.230~234 (2016), 대한진단검사의학회
- Jung YJ, "Comparison of the AdvanSure real-time RT-PCR and Seeplex(®) RV12 ACE assay for the detection of respiratory viruses", J Virol Methods, 224, pp.42~46 (2015)
- Bibby DF, "Comparative evaluation of the Seegene Seeplex RV15 and real-time PCR for respiratory virus detection", J Med Virol, 83, pp.1469~1475 (2011)
- Modjarrad K, "A roadmap for MERS-CoV research and product development: report from a World Health Organization consultation", Nat Med, 22, pp.701~705 (2016)
- Drosten C, "SARS molecular detection external quality assuranc", Emerg Infect Dis, 10, pp.2200~2203 (2004)
- "Interim guidelines for collecting, handling, and testing clinical specimens from patients under investigation (PUIs) for Middle East Respiratory Syndrome Coronavirus (MERS-CoV). V2.1"[URL]
- "Guidelins for MERS-CoV control"[URL]